Constipation treatment successful in late-stage trials

Symptoms of chronic constipation improve significantly following treatment with a new orally administered peptide, two Phase III trials have shown.

Complications of chronic constipation include haemorrhoids, faecal impaction (shown here on CT scan) and intestinal perforation | Photo: SPL
Complications of chronic constipation include haemorrhoids, faecal impaction (shown here on CT scan) and intestinal perforation | Photo: SPL

Linaclotide is a peptide agonist of guanylate cyclase type C, which is expressed on the epithelial cells that line the intestine. Activation of this receptor modulates abdominal pain sensation and secretion of fluid and electrolytes into the intestine.

The two trials, reported at this year's Digestive Disease Week, enrolled a total of 1,276 patients. Investigators randomised participants to receive 133 micrograms or 266 micrograms of linaclotide daily, or placebo, for 12 weeks. The study population was 89% female, with an average age of 48 years.

In both trials, the primary end point was achievement of three or more complete spontaneous bowel movements (CSBM) per week, with an increase from baseline of at least one CSBM per week for a minimum of nine weeks.

The results of the first trial showed that patients receiving linaclotide were more than twice as likely to respond to linaclotide as to placebo. The proportion of patients who achieved the primary end point was 16% in the group given 133 micrograms of linaclotide daily and 21.3% in the group on the 266 microgram dose, compared with 6% in the placebo group (p=0.0012 and p<0.0001, respectively, versus placebo).

In the second trial, the difference was even greater - 21.2% and 19.4% of patients receiving the lower and higher doses of linaclotide achieved the primary end point, respectively, compared with only 3.3% of those given placebo (p<0.0001 for both doses versus placebo).

Diarrhoea, flatulence and abdominal pain were the most commonly reported adverse events. At each dose of linaclotide, approximately 4% of patients discontinued treatment as a result of diarrhoea; the corresponding percentage in the placebo group was 0.5%.

Linaclotide, which is being developed in Europe by Almirall, is also undergoing Phase III testing for irritable bowel syndrome with constipation. Results from these trials are expected in the second
half of 2010.


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more